HIV-1 Nef Activators
HIV-1 Nef activators belong to a class of chemical compounds that interact with the Nef protein, which is a regulatory protein encoded by the nef gene in the Human Immunodeficiency Virus Type 1 (HIV-1). The nef gene is one of several accessory genes in the HIV-1 genome, and its product, the Nef protein, is a multifunctional protein crucial for enhancing the virus's ability to infect host cells and to evade the host immune response. The Nef protein achieves this through various mechanisms, including downregulation of cell surface receptors such as CD4 and major histocompatibility complex class I (MHC I), which are critical for the immune system's ability to recognize and respond to infected cells. Nef also modulates signaling pathways and cellular trafficking processes within the host cell. HIV-1 Nef activators, therefore, represent compounds that specifically modulate the activity of the Nef protein, typically by increasing its interaction with other cellular or viral components, or by stabilizing its structure to enhance its function.
The molecular architecture of these activators is diverse, reflecting the complex nature of the Nef protein's interactions and functions. These chemical entities are designed to bind to specific domains within the Nef protein, such as its SH3-binding domain or the acidic cluster-dileucine motif, which are known to be involved in the protein's interactions with other cellular proteins, including those of the host cell's signaling pathways. By engaging with these domains, the activators can potentially alter the conformation of Nef, which may affect its ability to associate with other proteins, such as adaptor proteins and kinases, thereby influencing its role in the viral life cycle.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ritonavir | 155213-67-5 | sc-208310 | 10 mg | $124.00 | 7 | |
Ritonavir, a protease inhibitor, disrupts HIV-1 replication by inhibiting the viral protease. By preventing the cleavage of viral polyproteins, Ritonavir hinders the maturation of infectious viral particles. This targeted interference with viral protease activity showcases Ritonavir's ability to impede the later stages of HIV-1 replication, ultimately suppressing the production of mature, infectious virions. | ||||||
Atazanavir | 198904-31-3 | sc-207305 | 5 mg | $292.00 | 7 | |
Atazanavir, a protease inhibitor, disrupts HIV-1 replication by inhibiting the viral protease. By preventing the cleavage of viral polyproteins, Atazanavir hinders the maturation of infectious viral particles. This targeted interference with viral protease activity showcases Atazanavir's ability to impede the later stages of HIV-1 replication, ultimately suppressing the production of mature, infectious virions. | ||||||
Indinavir | 150378-17-9 | sc-353630 | 100 mg | $982.00 | 1 | |
Indinavir, a protease inhibitor, disrupts HIV-1 replication by inhibiting the viral protease. By preventing the cleavage of viral polyproteins, Indinavir hinders the maturation of infectious viral particles. This targeted interference with viral protease activity showcases Indinavir's ability to impede the later stages of HIV-1 replication, ultimately suppressing the production of mature, infectious virions. | ||||||
Darunavir | 206361-99-1 | sc-218079 | 5 mg | $311.00 | 4 | |
Darunavir, a protease inhibitor, disrupts HIV-1 replication by inhibiting the viral protease. By preventing the cleavage of viral polyproteins, Darunavir hinders the maturation of infectious viral particles. This targeted interference with viral protease activity showcases Darunavir's ability to impede the later stages of HIV-1 replication, ultimately suppressing the production of mature, infectious virions. | ||||||
Lopinavir | 192725-17-0 | sc-207831 | 10 mg | $132.00 | 6 | |
Lopinavir, a protease inhibitor, disrupts HIV-1 replication by inhibiting the viral protease. By preventing the cleavage of viral polyproteins, Lopinavir hinders the maturation of infectious viral particles. This targeted interference with viral protease activity showcases Lopinavir's ability to impede the later stages of HIV-1 replication, ultimately suppressing the production of mature, infectious virions. | ||||||
Nelfinavir | 159989-64-7 | sc-507314 | 10 mg | $168.00 | ||
Nelfinavir, a protease inhibitor, disrupts HIV-1 replication by inhibiting the viral protease. By preventing the cleavage of viral polyproteins, Nelfinavir hinders the maturation of infectious viral particles. This targeted interference with viral protease activity showcases Nelfinavir's ability to impede the later stages of HIV-1 replication, ultimately suppressing the production of mature, infectious virions. | ||||||
Fosamprenavir Calcium Salt | 226700-81-8 | sc-218535 | 1 mg | $430.00 | ||
Fosamprenavir, a protease inhibitor, disrupts HIV-1 replication by inhibiting the viral protease. By preventing the cleavage of viral polyproteins, Fosamprenavir hinders the maturation of infectious viral particles. This targeted interference with viral protease activity showcases Fosamprenavir's ability to impede the later stages of HIV-1 replication, ultimately suppressing the production of mature, infectious virions. | ||||||
Tipranavir | 174484-41-4 | sc-220260 | 1 mg | $305.00 | 2 | |
Tipranavir, a protease inhibitor, disrupts HIV-1 replication by inhibiting the viral protease. By preventing the cleavage of viral polyproteins, Tipranavir hinders the maturation of infectious viral particles. This targeted interference with viral protease activity showcases Tipranavir's ability to impede the later stages of HIV-1 replication, ultimately suppressing the production of mature, infectious virions. | ||||||
Amprenavir | 161814-49-9 | sc-207287 sc-207287A | 5 mg 10 mg | $221.00 $402.00 | 2 | |
Amprenavir, a protease inhibitor, disrupts HIV-1 replication by inhibiting the viral protease. By preventing the cleavage of viral polyproteins, Amprenavir hinders the maturation of infectious viral particles. This targeted interference with viral protease activity showcases Amprenavir's ability to impede the later stages of HIV-1 replication, ultimately suppressing the production of mature, infectious virions. | ||||||